Genentech, Inc. Share Price

Stocks

End-of-day quote NYSE
- ^USD	-

17/15/17	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
30/-1/30	GENENTECH : profit rises, sales top estimates	RE

17/15/17	Fortescue Metals Group Limited Reports Unaudited Consolidated Earnings and Production Results for the Half Year Ended December 31, 2014; Provides Production Guidance for the Full Year of Fiscal 2015; Declares Fully Franked Interim Dividend for the Half Year Ended December 31, 2014, Payable on April 7, 2015	CI
30/-1/30	GENENTECH : profit rises, sales top estimates	RE
30/-1/30	GENENTECH : 3rd-quarter profit rises	RE
30/-1/30	GENENTECH : rejects Roche bid but willing to talk	RE
30/-1/30	GENENTECH : rejects Roche bid	RE
30/-1/30	GENENTECH : Roche buys Genentech for $46.8 billion	RE
30/-1/30	GENENTECH : Roche increases Genentech offer to $45.7 billion	RE
30/-1/30	GENENTECH : gives long-term forecast to fend off Roche	RE
30/-1/30	GENENTECH : to make case for higher purchase price	RE
30/-1/30	GENENTECH : asks shareholders to hold off on Roche bid	RE
30/-1/30	GENENTECH : Roche goes hostile, cuts Genentech bid to $42 billion	RE
30/-1/30	GENENTECH : forecast disappoints	RE
30/-1/30	GENENTECH : profit up, forecast light	RE

20/11/20	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
20/11/20	Genentech, Inc. : Dalradian Appoints Chief Operating Officer	PU
30/-1/30	GENENTECH : Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash	PR
30/-1/30	Genentech : Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer	BU
30/-1/30	Genentech : CORRECTING and REPLACING Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period and Completes Acquisition of Tanox	BU

12/16/12	Roche: la FDA homologue Venetoclax pour traiter une sorte de leucémie
11/16/11	Roche erhält von FDA Zulassung für Venetoclax zur Behandlung von Leukämie-Art
30/-1/30	Genentech : accroît de 7% son résultat net trimestriel.
30/-1/30	Genentech : l'offre de Roche considérée comme insuffisante.
30/-1/30	Genentech : s'envole après l'offre de Roche.

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.88%	+6.38%	+76.40%	+126.87%	1,11900Cr
JOHNSON & JOHNSON	+1.07%	+3.80%	+50.73%	+64.25%	65TCr
ABBVIE INC.	+1.20%	+6.21%	+25.81%	+80.15%	47TCr
ROCHE HOLDING AG	-1.42%	+4.07%	+42.59%	+42.46%	37TCr
NOVARTIS AG	-0.54%	+2.54%	+24.99%	+40.82%	30TCr
ASTRAZENECA PLC	-0.96%	+4.88%	+2.12%	+12.78%	26TCr
AMGEN INC.	+1.29%	+5.81%	+49.57%	+70.71%	24TCr
NOVO NORDISK A/S	+0.28%	+3.23%	-17.82%	-53.26%	21TCr
GILEAD SCIENCES, INC.	+1.87%	+5.61%	+27.32%	+89.67%	18TCr
Average	+0.40%	+5.17%	+31.30%	+52.72%	42.22TCr
Weighted average by Cap.	+0.52%	+5.40%	+44.12%	+72.32%

Employees

Sector